Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tosedostat plus standard induction therapy in AML and RAEB
2009-014455-68Phase 2Active
- Sponsor
- HOVON
- Start
- Nov 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of tosedostat in acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts (MDS-EB) (2 arms), sponsored by HOVON. Primary endpoint: Dose-limiting toxicity incidence (DLT). Started Nov 2009; status: active.
02
Drugs
tosedostat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome with excess blasts (MDS-EB)
Beyond the preview
Go deeper on 2009-014455-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014455-68.